UK, EU regulators confirm safety of AstraZeneca’s Covid-19 vaccine
MHRA concluded that there is no evidence that blood clots in veins are occurring more than expected in…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
19 Mar 21
MHRA concluded that there is no evidence that blood clots in veins are occurring more than expected in…
18 Mar 21
Sana Biotechnology will use the iPSC cell lines from Fujifilm Cellular Dynamics to research, develop, manufacture, and commercialise…
17 Mar 21
AbbVie has acquired the portfolio of women's drugs as part of its $63bn acquisition of Allergan, completed last…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
16 Mar 21
Takeda will use the IDT’s capacity, previously reserved for its dengue vaccine candidate (TAK-003), to produce Janssen’s Covid-19…
15 Mar 21
Earlier, the Republic of Ireland took a similar decision over reports of blood clotting in adults in Norway
12 Mar 21
EC authorised the vaccine to prevent the Covid-19 in people aged 18 years and older, in all 27…
12 Mar 21
The MoH analysis showed at least 97% vaccine effectiveness against symptomatic Covid-19 cases, and 94% against asymptomatic SARS-CoV-2…
11 Mar 21
AVEO claimed that Fotivda is the first FDA approved therapy for relapsed or refractory advanced renal cell carcinoma…
10 Mar 21
Takeda will obtain Maverick’s T-cell engager COBRA platform and its lead development candidates TAK-186 (MVC-101) and TAK-280 (MVC-280)
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
09 Mar 21
Biolojic will receive up to $121m, including potential milestones and a promissory note, along with tiered royalties on…